Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 24

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 24
---
 issued to the investors warrants to purchase 1,384,722 shares of our common stock, exercisable at $8.302 per share
and expiring on July 27, 2030. The total gross proceeds were approximately $5.7 million and placement agent fees and other
offering expenses were approximately $0.8 million.

5

In
February 2025, we entered into a SEPA with Yorkville, pursuant to which we have the right, but not the obligation, to sell up to $20.0
million of our common stock during a 36 months period, subject to the restrictions and satisfaction of the conditions in the SEPA. Upon
execution of the SEPA, we issued to Yorkville 10,927 commitment shares. During the first six months of 2025, we sold 89,902 shares of
common stock under the SEPA for aggregate net proceeds of approximately $1.75 million, after deducting offering expenses in the amount
of approximately $0.1 million.

In
January 2025, we completed a private placement (the “January 2025 Financing”) for the sale and issuance by us of an aggregate
of: (i) 75,335 shares of our common stock and (ii) warrants to purchase 75,335 shares of common stock. The shares and warrants were sold
on a combined basis for consideration of $29.82 for one share and one warrant for aggregate gross proceeds of approximately $2.25 million.

In
June 2022, we entered into an At The Market Offering Agreement (the “ATM Agreement”) which was amended on September 1, 2022
with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which we may offer and sell, from time to
time through Wainwright, shares of our common stock, par value $0.01 per share, for aggregate gross proceeds of up to $3.7 million. The
issuance and sale of common stock by us under the ATM Agreement is being made pursuant to our effective “shelf” registration
statement on Form S-3 filed with the SEC on September 1, 2022 and declared effective on September 9, 2022. In 2024, we sold 5,428 shares
of our common stock for aggregate gross proceeds of approximately $0.4 million. On August 6, 2024, we filed a prospectus